Information Provided By:
Fly News Breaks for March 2, 2020
FTSV, GILD
Mar 2, 2020 | 09:42 EDT
Roth Capital analyst Tony Butler downgraded Forty Seven (FTSV) to Neutral from Buy with a price target of $95.50, up from $55, after the company reached an agreement to be acquired by Gilead Sciences (GILD). The analyst believes Gilead strengthend its immuno-oncology portfolio with the acquisition of Forty Seven's CD47-targeting monoclonal antibody magrolimab.
News For FTSV;GILD From the Last 2 Days
GILD
Jun 1, 2020 | 16:36 EDT
Specialty Pharma Analysts Chen & Kim and Biopharma Analyst Folkes discuss the unment needs in the treatment of Type 2 Diabetes, NASH and Obesity, Novo's Rybelsus usage, Eli Lilly's Trulicity and Tirzepatide and a review of NASH treatments in development from Gilead, Novo, Intercept and CymaBay on an Analyst/Industry conference call to be held on June 5 at 11 am.
GILD
Jun 1, 2020 | 11:58 EDT
Stocks are extending their recent rally despite an increasing number of U. S... To see the rest of the story go to thefly.com. See Story Here
GILD
Jun 1, 2020 | 08:53 EDT
Gilead Sciences shares are down $1.60, or 2%, to $76.23 in pre-market trading after the company announced earlier topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia.